RegimenIndicationStudy NameEarly StageMid StageLate StageCommercial

XPOVIO

w/dexamethasone

Multiple myeloma (penta-refractory)STORM
Early Stage
Mid Stage
Late Stage
Commercial

w/bortezomib + dexamethasone

Multiple myeloma (2L+)BOSTON
Early Stage
Mid Stage
Late Stage
Commercial

monotherapy

DLBCL (R/R)SADAL
Early Stage
Mid Stage
Late Stage
Commercial

SELINEXOR

RegimenIndicationStudy NameEarly StageMid StageLate StageCommercial

SELINEXOR

w/R-GDP

DLBCL (R/R)XPORT-DLBCL-030
Early Stage
Mid Stage
Late Stage
Commercial

monotherapy

Endometrial Cancer (maintenance)SIENDO
Early Stage
Mid Stage
Late Stage
Commercial

monotherapy

Endometrial cancer (maintenance; p53 wild-type)
Early Stage
Mid Stage
Late Stage
Commercial

w/pomalidomide + dexamethasone

Multiple myeloma (2L+)XPORT-MM-031
Early Stage
Mid Stage
Late Stage
Commercial

w/standard approved therapies

Multiple myeloma (relapsed/refractory)STOMP
Early Stage
Mid Stage
Late Stage
Commercial

monotherapy

Myelofibrosis (previously treated)XPORT-MF-035
Early Stage
Mid Stage
Late Stage
Commercial

w/ ruxolitinib

Myelofibrosis (treatment naïve)XPORT-MF-034
Early Stage
Mid Stage
Late Stage
Commercial

ELTANEXOR

RegimenIndicationStudy NameEarly StageMid StageLate StageCommercial

ELTANEXOR

monotherapy

Myelodysplastic syndromes (refractory)KCP-8602-801
Early Stage
Mid Stage
Late Stage
Commercial

+ hypomethylating agents

Myelodysplastic syndromes
(newly diagnosed)
KCP-8602-801
Early Stage
Mid Stage
Late Stage
Commercial
Hematologic Cancer
Solid Tumor Cancer
Coming Soon